Business
Cryo-Cell provides private umbilical cord blood and cord tissue stem-cell processing and storage, with smaller public banking and PrepaCyte-CB activities.
Cryo-Cell posted positive FY2025 FCF and heavy insider buying, but net income swung to a loss and equity stayed deeply negative.
The read at a glance✓ Audited against SEC data
- Business mix — Cord blood storageNote
- Net income — ($2.4M), lossWatch
- FCF — $5.2M, +45.5%OK
- Dividends — $3.2M, +59.9%OK
- Equity — ($18.6M), deficitWatch
- Insiders — $288.7K purchases and 0 salesOK
- Accounting — Forensic screen unavailableNote
Where the revenue comes from
Fiscal 2025, as CRYO CELL INTERNATIONAL INC reports it. History and quarterly detail are in the app.
- Umbilical Cord Blood And Cord Tissue Stem Cell Service$31.4M
- Public Cord Blood Banking$130K
- Prepacytecb$54K
Latest filings
- 10-Q · Quarterly report2026-07-15
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-04-14
- 8-K · Company announcement2026-03-12
- 10-K · Annual report2026-02-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CRYO CELL INTERNATIONAL INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.